Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It also distributes cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. It serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. Pressure BioSciences, Inc. has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts.
IPO Year: n/a
Exchange: NASDAQ
Website: pressurebiosciences.com
10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
NT 10-Q - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
8-K - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
8-K - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
10-K - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
8-K - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
NT 10-K - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
DEF 14A - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
8-K - PRESSURE BIOSCIENCES INC (0000830656) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
4 - PRESSURE BIOSCIENCES INC (0000830656) (Issuer)
Fastest customizable press release news feed in the world
CANTON, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Thursday, June 20, 2024 at 4:30pm ET. Topics to be discussed include: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Status of Company's new Joint Venture Program.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 release of new nanoemulsified products, i
SOUTH EASTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics. The teleconference is scheduled for Wednesday, June 19, 2024 at 4:30 PM ET. The topics to be discussed include but are not limited to: FY 2023 financial and business results.FY 2024 financial and business outlook.Status of Company's relocation to its new manufacturing facility.Update on Uncle Bud's Health and WellnessProduct expansion – expected Q3/Q4 2024 commercial release of new nanoemulsified products: N
SOUTH EASTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today revealed that its wholly-owned Uncle Bud's Health & Wellness direct-to-consumer ("DTC") subsidiary ("Uncle Bud's") has announced an expansion of products and categories in 2024 to its recently formed "Premium Collection" of state-of-the-art nanoemulsified products. Premium Collection products
PBIO Receives Critical Processor License for Industrial Hemp in MA.New License and Relocation to Enhanced Manufacturing Facility Allows Company to Supplement Production with West Coast Partner to Manage Anticipated Onset of Purchase Order Increases. CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced that its wholly-owned Uncle Bud's H
SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB"). Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, inc
CANTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, pharmaceutical, and other industries, today celebrated a significant milestone in its accelerating growth journey. The Company announced the consolidation of its Boston area operations, uniting all of its personnel into a single, cutting-edge facility designed to accommodate expanded R&D capabilities, advanced equipment development and production, formulati
Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe
SOUTH EASTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced that the Company will host a teleconference to discuss the recent strategic acquisition of natural health and wellness innovator Uncle Bud's ("UB") in an all-stock transaction. In particular, the Company will discuss its current, in-process move to new, more efficient
SOUTH EASTON, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced the closing of its acquisition of natural health and wellness leader Uncle Bud's ("UB") in an all-stock transaction. Incorporating UB's 70+ already popular products, 865K member on-line community, existing sales channels online and with leading large retailers, enviab
SOUTH EASTON, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, announced on January 11, 2024 the execution of a definitive agreement (the "Asset Purchase Agreement", or "APA") to acquire renowned natural health and wellness leader Uncle Bud's. Today, the Company announced the beginning of summer season order filling with one of the globe's leadi
Live Leadership Updates
SOUTH EASTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biotherapeutics, and more, is excited to announce promising early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness ("UB"). Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, inc
Live finance-specific insights
Multi-Patented Nanoemulsification Platform Enables Wide-Range of Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in 2024 Anticipated with Further Acceleration in 2025 & Beyond Pressure BioSciences February 5th Investor Call to Discuss Impact of Recent Uncle Bud's Acquisition SOUTH EASTON, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including health and wellness, nutraceuticals, food and beverage, cosmetics, biothe
Investor Call Scheduled for Tuesday, November 21, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the third quarter ended September 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q3 2023 vs. Q3 2022 (rounded to nearest
Conference Call Scheduled for Tuesday, November 21 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 20, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2023 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 21, 2023. Time: 4:30 PM Eastern Time (ET).To attend thi
Investor Call Scheduled for Tuesday, August 22, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / August 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmeceuticals, agriculture, and food & beverage industries, today reported financial results for the second quarter ended June 30, 2023, provided a business update, and offered limited guidance for expected achievements through the remainder of 2023.Financial Highlights: Q2 2023 vs. Q2 2022 (rounded to nearest hundred
Validated Nanoemulsion Capabilities Are Transformative Across Multiple Major Markets, New $1.5M Contract, New Manufacturing Facility, and Reduced Cash Burn Set Stage for Expected Strong FY 2023Investor Call Scheduled for Tuesday May 16, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / May 16, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a leader in the development and sale of broadly enabling, high pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food & beverage, and other industries, today reported that record quarterly financial results for any fiscal quarter was achieved
Company Pivots Strongly into Revolutionary UltraShear Platform, Achieving Measurable Progress and Traction, Including Expected Record Revenue in Q1 2023Investor Call Scheduled for Tuesday, April 18, 2023 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / April 14, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, reported financial results for the fourth quarter and fiscal year ended December 31, 2022, provided a business update, and offered guidance for a strong 2023, beginning with record revenue in the 2023 first quarter.F
Conference Call Scheduled for Tuesday, April 18 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / April 13, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fiscal Year 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, April 18, 2023. Time: 4:30 PM Eastern Time (ET).To attend this teleconfer
Company's Largest Investor Exchanges First Seniority Debt into Non-Secured Equity at 38% Above-Market Price, Expressing Confidence and SupportSOUTH EASTON, MA / ACCESSWIRE / March 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBIO" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, today announced that the Company's largest shareholder has exchanged over $10 million of senior secured debt into unsecured preferred stock. The debt being converted is comprised of convertible promissory notes, accrued and unpaid interest on all promissory notes issued to the investor since
Resources Continue to Pivot to UST Platform Commercialization, Achieving Major Progress and Traction; Revolutionary Nanoemulsions Technology Expected to Drive Major Growth to Profitability in 2023Investor Call Scheduled for Tuesday, November 22, 2022 at 4:30 p.m. ETSOUTH EASTON, MA / ACCESSWIRE / November 22, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agrochem, and food & beverage industries, today reported financial results for the
Conference Call Scheduled for Tuesday November 22 at 4:30pm ETSOUTH EASTON, MA / ACCESSWIRE / November 21, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2022 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company's website) approximately one day after the teleconference.The teleconference will include a Company presentation followed by a Question & Answer period.Date: Tuesday, November 22, 2022. Time: 4:30 PM Eastern Time (ET).To attend this
This live feed shows all institutional transactions in real time.
SC 13G/A - PRESSURE BIOSCIENCES INC (0000830656) (Subject)
SC 13G - PRESSURE BIOSCIENCES INC (0000830656) (Subject)